<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895528</url>
  </required_header>
  <id_info>
    <org_study_id>EIG-EAP-LNF-001</org_study_id>
    <nct_id>NCT03895528</nct_id>
  </id_info>
  <brief_title>Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy</brief_title>
  <official_title>A Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid Laminopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eiger BioPharmaceuticals</source>
  <brief_summary>
    <textblock>
      This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access&#xD;
      to lonafarnib, the only compound shown to have an effect on the HGPS disease process&#xD;
      resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for&#xD;
      HGPS and progeroid laminopathies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Progeria</condition>
  <condition>HGPS</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonafarnib</intervention_name>
    <description>Farnesyl transferase inhibitor</description>
    <other_name>FTI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of HGPS or progeroid laminopathy by qualified medical doctor (based&#xD;
             on common phenotype as described in Gordon 2015 and Merideth 2008). Confirmation with&#xD;
             genetic testing is preferred but not required.&#xD;
&#xD;
          -  Adequate hepatic function as defined by SGPT (ALT) and SGOT (AST) â‰¤ 5 times upper&#xD;
             limit of normal range for age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking medications or foods that are known to be moderate or strong inducers or&#xD;
             inhibitors of CYP3A4 or sensitive CYP3A substrates; or if a patient is taking one of&#xD;
             these drugs and cannot safely discontinue or take an alternative drug, the dose of the&#xD;
             inhibitor/inducer must be adjusted per the treating physician&#xD;
&#xD;
          -  Taking digoxin, a P-gp substrate with a narrow therapeutic window.&#xD;
&#xD;
          -  Severe renal impairment (GFR &lt; 30 mL/min/1.73m2).&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  Presence of any active clinically relevant medical condition that in the opinion of&#xD;
             the treating physician would preclude patient from safely participating in the&#xD;
             program.&#xD;
&#xD;
          -  Pregnant or breast-feeding or plan to become pregnant while on therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <reference>
    <citation>Gordon LB, Shappell H, Massaro J, D'Agostino RB Sr, Brazier J, Campbell SE, Kleinman ME, Kieran MW. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018 Apr 24;319(16):1687-1695. doi: 10.1001/jama.2018.3264.</citation>
    <PMID>29710166</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progeria</mesh_term>
    <mesh_term>Laminopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

